Echo Therapeutics Inc fka ECTE

[biocqr]

New video demonstrates Prelude and Symphony...

http://www.echotx.com/


PHILADELPHIA , Aug. 9, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the unveiling of a much anticipated demonstration video on the Company's website at www.echotx.com.  The new video showcases the features and ease of use of the Symphony continuous glucose monitoring system in a home setting.  The Company has released this demonstration video as a result of increasing demands from patients and investors for information regarding how the Symphony tCGM System works.
The launch of the video coincides with the final steps in the planning and preparation of the upcoming clinical study testing the next generation Symphony tCGM System design, which will commence in the near-term.  
"We are excited to feature the demonstration video on our website in order to illustrate the ease of using Symphony. We believe that Symphony will be an important and differentiated candidate for glucose monitoring that has the potential to change the paradigm of invasive, episodic glucose monitoring.  We believe that the ease of use and needle-free, wireless and continuous features and benefits will improve patient compliance to frequent glucose testing and lead to better long term outcomes for patients," said Patrick T. Mooney , M.D., Chairman and CEO of Echo Therapeutics .  "More than ever, we are enthusiastic about the potential of Symphony and we look forward to the commencement of the upcoming clinical study."